1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tyche Industries Limited

Tyche Industries Limited

BBSE:TYCHE
104.90
INR
+1.70
(+1.65%)
4.26EPS
30.13P/E
1.31BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
101.98
62.43
52.86
41.73
50.36
52.79
71.94
76.37
60.78
73.58
67.85
63.91
52.35
47.8
Basic EPS, GAAP
5.4
1.89
2.41
3.02
5.72
6.97
17.14
19.51
9.11
13.83
11.95
12.11
6.77
4.26
Free Cash Flow per Basic Share
2.24
1.24
10.45
11.07
3.53
2.51
14.53
12.64
3.39
4.57
4.38
7.63
-1.37
- -
Dividend per Share
0.5
0.6
0.6
0.5
0.5
- -
0.5
1
1
1.5
2
2.5
3
- -
Book Value per Share
42.52
42.72
44.47
46.72
51.88
58.85
75.29
93.62
101.68
113.91
123.64
133.37
137.04
- -
Tangible Book Value per Share
42.52
42.72
44.47
46.72
51.88
58.85
75.29
93.62
101.68
113.91
123.64
133.37
137.04
- -
Basic Weighted Avg Shares
10
10
10
10
10
10
10
10
10
10
10
10
10
10
Sales/Revenue/Turnover
1,043
639
541
426
516
541
737
782
623
754
695
655
536
500
Operating Margin (%)
8.89
5.93
2.14
9.98
13.92
13.84
27.44
30.87
15.9
19.36
15.65
15.32
1.43
-7.13
Depreciation Expense
14
33
18
19
18
18
17
17
18
18
19
20
20
22
Net Income, GAAP
55
19
25
31
59
71
176
200
93
142
122
124
69
45
Effective Tax Rate (%)
32.32
32.53
3.34
48.05
33.87
27.42
24.72
25.25
26.15
25.74
26.38
25.76
26.7
27.54
Profit Margin (%)
5.29
3.02
4.56
7.23
11.36
13.21
23.82
25.54
14.99
18.8
17.61
18.95
12.93
8.91
Working Capital
133
149
167
220
344
421
603
785
882
959
1,064
1,113
1,014
- -
LT Debt
10
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
436
438
456
479
531
603
772
960
1,042
1,168
1,267
1,367
1,405
- -
Return on Invested Capital (%)
12.64
4.81
2.05
4.11
9.82
9.58
22.16
20
6.83
9.7
6.54
5.64
0.5
- -
Return on Capital (%)
12.18
4.96
5.04
5.99
11.6
12.59
25.55
23.09
9.32
12.83
10.06
9.42
5.01
- -
Return on Common Equity (%)
13.43
4.42
5.52
6.59
11.61
12.6
25.55
23.08
9.32
12.83
10.06
9.42
5.01
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
1,187
1,023
1,314

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,079
- -
Cash, Cash Equivalents & STI
- -
719
- -
Accounts Receivable, Net
- -
195
- -
Inventories
- -
99
- -
Total Current Liabilities
- -
66
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.16%
7.96%
2.76%
Free Cash Flow
28.94%
-17.2%
-117.94%
Net Income, GAAP
23.89%
-11.56%
-44.09%
Sales/Revenue/Turnover
1.61%
-6.21%
-18.08%
Total Cash Common Dividend
- -
- -
20%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
155
205
178
124
655
2026
127
142
106
162
536
2027
91
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.66
3.9
4.63
1
12.11
2026
2.37
1.49
1.78
1.05
6.77
2027
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
3
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sandeep Gokaraju
Full Time Employees
167
Sector
Health technology
Industry
Pharmaceuticals: major
Address
H. No. C 21 Hyderabad TS India 500096
IPO Date
Sep 25, 2000
Website
tycheindustries.net
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tyche Industries Limited manufactures active pharmaceutical ingredients, advanced and chiral intermediates, and nutraceuticals in India for export primarily to the United States and Europe; the company offers contract development and manufacturing organization services, analytical development, and custom synthesis or toll manufacturing of fine and specialty chemicals. Incorporated in 1998 and headquartered in Hyderabad, Telangana, with manufacturing facilities in Kakinada, Andhra Pradesh, it maintains good manufacturing practice standards and targets pharmaceutical and biotech customers globally. In 2025, the company successfully completed a GMP inspection by Brazil's ANVISA regulatory agency at its Kakinada facility, announced leadership changes including the appointment of Sandeep Gokaraju as Chairman and Managing Director replacing G Ganesh Kumar, and initiated a 30% dividend payout for FY 2024-25.